FindTrial
Sign In

A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination with Gemcitabine in Patients with Advanced or Metastatic Cancer with a Focus on Ovarian Cancer

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-503459-91-00
Acronym
ESPS-001(m)
Enrollment
12
Registered
2023-08-28
Start date
2023-11-21
Completion date
2025-04-07
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or Metastatic Cancer

Brief summary

Safety (treatment emergent adverse events, serious adverse events, and clinical abnormalities per Common Terminology Criteria for Adverse Event)

Detailed description

overall response rate, disease control rate

Interventions

DRUGGemcitabine Kabi 38 mg/ml koncentrát pro infuzní roztok
DRUGGEMSOL
DRUG40 MG/ML
DRUGKONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI

Sponsors

Esperas Pharma Inc., Esperas Pharma Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Safety (treatment emergent adverse events, serious adverse events, and clinical abnormalities per Common Terminology Criteria for Adverse Event)—

Secondary

MeasureTime frame
overall response rate, disease control rate—

Countries

Croatia, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026